US Heparin Market

ID: MRFR/MED/51000-HCR 200 Pages Satyendra Maurya Last Updated: September 17, 2026
US Heparin Market Research Report By Product (Unfractionated Heparin (UFH), Low Molecular Weight Heparin (LMWH)), By Source (Bovine, Porcine), By Application (Deep Vein Thrombosis & Pulmonary Embolism, Atrial Fibrillation, Heart Attacks, Stroke, Others), By Route of Administration (Intravenous Infusion, Subcutaneous Injection) and By End user (Hospitals & ASCS, Clinics, Others) - Growth & Industry Forecast 2025 To 2035
US Heparin Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)3.02%
2024 Market Size$ 2,250 Million
2025 Market Size$ 2,317.95 Million
2035 Market Size$ 3,120 Million
Key Players
Baxter International Inc
Sanofi
Pfizer Inc
Novartis AG
Boehringer Ingelheim GmbH
Mylan N.V.
Trends
  • Rising Demand for Anticoagulants
  • Innovations in Pharmaceutical Formulations
  • Regulatory Enhancements and Quality Assurance
Opportunities
  • Rising Geriatric Population
  • Advancements in Surgical Procedures
  • Increased Focus on Preventive Healthcare
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Medical Device, BY Product (USD Million)
      1. 4.1.1 Unfractionated Heparin (UFH)
      2. 4.1.2 Low Molecular Weight Heparin (LMWH)
    2. 4.2 Medical Device, BY Source (USD Million)
      1. 4.2.1 Bovine
      2. 4.2.2 Porcine
    3. 4.3 Medical Device, BY Application (USD Million)
      1. 4.3.1 Deep Vein Thrombosis & Pulmonary Embolism
      2. 4.3.2 Atrial Fibrillation
      3. 4.3.3 Heart Attacks
      4. 4.3.4 Stroke
      5. 4.3.5 Others
    4. 4.4 Medical Device, BY Route of Administration (USD Million)
      1. 4.4.1 Intravenous Infusion
      2. 4.4.2 Subcutaneous Injection
    5. 4.5 Medical Device, BY End user (USD Million)
      1. 4.5.1 Hospitals & ASCS
      2. 4.5.2 Clinics
      3. 4.5.3 Others
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Medical Device
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Medical Device
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Baxter International Inc (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Sanofi (FR)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Pfizer Inc (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Novartis AG (CH)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Boehringer Ingelheim GmbH (DE)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Mylan N.V. (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Teva Pharmaceutical Industries Ltd (IL)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Aspen Pharmacare Holdings Limited (ZA)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY PRODUCT
    3. 6.3 US MARKET ANALYSIS BY SOURCE
    4. 6.4 US MARKET ANALYSIS BY APPLICATION
    5. 6.5 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    6. 6.6 US MARKET ANALYSIS BY END USER
    7. 6.7 KEY BUYING CRITERIA OF MEDICAL DEVICE
    8. 6.8 RESEARCH PROCESS OF MRFR
    9. 6.9 DRO ANALYSIS OF MEDICAL DEVICE
    10. 6.10 DRIVERS IMPACT ANALYSIS: MEDICAL DEVICE
    11. 6.11 RESTRAINTS IMPACT ANALYSIS: MEDICAL DEVICE
    12. 6.12 SUPPLY / VALUE CHAIN: MEDICAL DEVICE
    13. 6.13 MEDICAL DEVICE, BY PRODUCT, 2024 (% SHARE)
    14. 6.14 MEDICAL DEVICE, BY PRODUCT, 2024 TO 2035 (USD Million)
    15. 6.15 MEDICAL DEVICE, BY SOURCE, 2024 (% SHARE)
    16. 6.16 MEDICAL DEVICE, BY SOURCE, 2024 TO 2035 (USD Million)
    17. 6.17 MEDICAL DEVICE, BY APPLICATION, 2024 (% SHARE)
    18. 6.18 MEDICAL DEVICE, BY APPLICATION, 2024 TO 2035 (USD Million)
    19. 6.19 MEDICAL DEVICE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
    20. 6.20 MEDICAL DEVICE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
    21. 6.21 MEDICAL DEVICE, BY END USER, 2024 (% SHARE)
    22. 6.22 MEDICAL DEVICE, BY END USER, 2024 TO 2035 (USD Million)
    23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY PRODUCT, 2025-2035 (USD Million)
      2. 7.2.2 BY SOURCE, 2025-2035 (USD Million)
      3. 7.2.3 BY APPLICATION, 2025-2035 (USD Million)
      4. 7.2.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
      5. 7.2.5 BY END USER, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US US Heparin Market Segmentation

US Heparin Market By Product (USD Million, 2025-2035)

  • Unfractionated Heparin (UFH)
  • Low Molecular Weight Heparin (LMWH)

US Heparin Market By Source (USD Million, 2025-2035)

  • Bovine
  • Porcine

US Heparin Market By Application (USD Million, 2025-2035)

  • Deep Vein Thrombosis & Pulmonary Embolism
  • Atrial Fibrillation
  • Heart Attacks
  • Stroke
  • Others

US Heparin Market By Route of Administration (USD Million, 2025-2035)

  • Intravenous Infusion
  • Subcutaneous Injection

US Heparin Market By End user (USD Million, 2025-2035)

  • Hospitals & ASCS
  • Clinics
  • Others

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.